RDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL.

NCT06250959 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

124

Enrollment

OTHER

Sponsor class

Conditions

ALL, Adult
Philadelphia-Negative ALL

Interventions

DRUG: Blinatumomab Injection [Blincyto]
DRUG: Doxorubicin

Sponsor

Chen Suning